Orbimed Advisors LLC Oric Pharmaceuticals, Inc. Transaction History

Orbimed Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.04 - $16.03 $1.9 Million - $3.78 Million	-235,868 Reduced 45.1%	287,100 $3.95 Million
Q4 2023 Feb 14, 2024	SELL	$5.41 - $9.43 $2.01 Million - $3.5 Million	-370,700 Reduced 41.48%	522,968 $4.81 Million
Q3 2023 Nov 14, 2023	SELL	$6.05 - $9.28 $1.66 Million - $2.55 Million	-274,800 Reduced 23.52%	893,668 $5.41 Million
Q2 2023 Aug 14, 2023	SELL	$4.95 - $8.4 $1.02 Million - $1.73 Million	-206,000 Reduced 14.99%	1,168,468 $9.07 Million
Q1 2023 May 15, 2023	SELL	$4.26 - $6.75 $993,006 - $1.57 Million	-233,100 Reduced 14.5%	1,374,468 $7.83 Million
Q4 2022 Feb 14, 2023	SELL	$2.41 - $5.89 $1.16 Million - $2.83 Million	-480,000 Reduced 22.99%	1,607,568 $9.47 Million
Q1 2022 May 16, 2022	SELL	$4.54 - $16.1 $1.14 Million - $4.03 Million	-250,006 Reduced 10.7%	2,087,568 $11.1 Million
Q1 2021 May 17, 2021	SELL	$23.67 - $36.85 $13.8 Million - $21.5 Million	-584,393 Reduced 20.0%	2,337,574 $57.3 Million
Q2 2020 Aug 14, 2020	BUY	$25.68 - $38.12 $75 Million - $111 Million	2,921,967 New	2,921,967 $98.6 Million

124

66.6M

7.8K

700

Ticker ORIC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,576,700
Market Cap $325M
Description
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.